Evaxion Biotech AS company info

What does Evaxion Biotech AS do?
Evaxion Biotech AS (NASDAQ:EVAX) is a pioneering entity concentrated on leveraging artificial intelligence (AI) to discover and develop novel immunotherapies for cancer, infectious diseases, and autoimmune disorders. Operating at the intersection of biotechnology and AI, Evaxion aims to revolutionize the way diseases are treated by harnessing the power of the human immune system, guided by cutting-edge computational platforms. The company's projects span a wide range of applications, from personalized cancer vaccines to broad-spectrum antibacterials, with the objective to significantly improve patient outcomes by making therapies more effective, safer, and accessible. Committed to innovation, Evaxion is driven by a fervent desire to address unmet medical needs, positioning itself as a forward-thinking player in the biotech industry.
Evaxion Biotech AS company media
Company Snapshot

Is Evaxion Biotech AS a public or private company?

key
Ownership
Public

How many people does Evaxion Biotech AS employ?

people
Employees
49

What sector is Evaxion Biotech AS in?

pie chart
Sector
Health Care

Where is the head office for Evaxion Biotech AS?

location pin
Head Office
Copenhagen, Denmark

What year was Evaxion Biotech AS founded?

founded flag
Year Founded
2008
What does Evaxion Biotech AS specialise in?
/Immunotherapy Solutions /Cancer Treatments /P-DARTS Platform /AI Biotechnology /Infectious Diseases /RAPP System

What are the products and/or services of Evaxion Biotech AS?

Overview of Evaxion Biotech AS offerings
PIONEER personalized cancer immunotherapy, utilizing AI to design patient-specific treatments.
EVX-01, a personalized cancer vaccine targeting melanoma, leveraging AI for enhanced specificity.
EVX-02, another personalized cancer vaccine, aiming at adjuvant melanoma but with distinct antigens.
EVX-03, focusing on DNA-based therapies for infectious diseases, harnessing AI for rapid pathogen identification.
AI-powered platform for rapid antibody discovery, streamlining therapeutic antibody development against infectious diseases.
EVX-B1, a vaccine in development against Staphylococcus aureus, intending to prevent infections in healthcare settings.

Who is in the executive team of Evaxion Biotech AS?

Evaxion Biotech AS leadership team
  • Mr. Christian  Kanstrup M.Sc.
    Mr. Christian Kanstrup M.Sc.
    Chief Executive Officer
  • Mr. Andreas Holm Mattsson
    Mr. Andreas Holm Mattsson
    Co-Founder and Chief AI & Culture Officer
  • Mr. Jesper Nyegaard Nissen M.Sc.
    Mr. Jesper Nyegaard Nissen M.Sc.
    Interim CFO & COO
  • Dr. Niels Iversen Moeller M.D.
    Dr. Niels Iversen Moeller M.D.
    Co-Founder, VP of Business & Director
  • Dr. Birgitte  Rono Ph.D.
    Dr. Birgitte Rono Ph.D.
    Chief Scientific Officer
  • Dr. Jürgen  Langhärig EMBA, Ph.D.
    Dr. Jürgen Langhärig EMBA, Ph.D.
    Head of Business Development & Member of Advisory Board